10 High Cost Drugs Losing Patent Protection in 2016


Generic drugs are generally lower cost for insurers than brand name drugs. Here are 10 drugs coming off patent in 2016. Although the FDA has not yet approved generics for these drugs they are in the pipeline. The drugs are listed below:

1. Humira - used for: Rheumatoid arthritis

Manufactured by: Abbvie

Estimated annual sales: $12.54 billion

Generic approved: Biosimilars in the pipeline, no generic approved

2. Crestor - used for: Lower bad cholesterol (LDL), raise good cholesterol

Manufactured by: AstraZeneca

Estimated annual sales: $6.4 billion

Generic approved: N/A

3. Benicar - used for: High blood pressure

Manufactured by: Daiichi Sankyo

Estimated annual sales: $2.6 billion

Generic approved: N/A

4. Zetia - used for: High cholesterol

Manufactured by: Merck

Estimated annual sales: $2.6 billion

Generic approved: N/A

5. Seroquel XR - used for: Schizophrenia and bipolar disorder

Manufactured by: AstraZeneca

Estimated annual sales: $1.3 billion

Generic approved: N/A

6. AcipHex Sprinkle - used for: Acid reflux, ulcers

Manufactured by: Eisai

Estimated annual sales: $1.2 billion

Generic approved: November 2013

7. Epzicon - used for: HIV

Manufactured by: Viiv Healthcare

Estimated annual sales: $1.1 billion

Generic approved: N/A

8. Kaletra - used for: HIV

Manufactured by: Abbott

Estimated annual sales: $1 billion

Generic approved: N/A

9. Norvir - used for: HIV

Manufactured by: Abbott

Estimated annual sales: $962 million

Generic approved: Jan 15, 2015

10. Ambisome - used for: anti-fungal medicine

Manufactured by: Gilead

Estimated annual sales: $493 million

Generic approved: N/A

#prescriptiondrugs

Featured Posts
Recent Posts